The plant toxin ricin is considered a biological threat agent of concern and is most toxic when inhaled. Pulmonary exposure to a lethal dose of ricin can be redressed by treatment with antiricin antibodies; however, late antitoxin intervention is of limited efficacy. This limitation is associated with overt lung damage, clinically manifested as severe pulmonary inflammation, which develops over time. Increased evidence indicates that ciprofloxacin, a broad-spectrum antimicrobial agent, possesses immunomodulatory properties. Here we demonstrate that while antiricin antibody administration at late hours after intranasal exposure to ricin confers limited protection to mice, highly efficient protection can be achieved by adding ciprofloxacin to the antibody treatment. We further demonstrate that parameters associated with lung injury, in particular, pulmonary proinflammatory cytokine production, neutrophil migration, and edema, are sharply reduced in ricin-intoxicated mice that were treated with ciprofloxacin. The presented data highlight the potential clinical application of ciprofloxacin as a beneficial immunomodulatory agent in the course of ricin intoxication.
Ricin, a type II ribosome-inactivating protein, is a plant toxin derived from the seeds of Ricinus communis (castor beans). The holotoxin consists of two polypeptide chains (A and B) linked by a disulfide bond. The B chain is a lectin, which binds to galactose residues on the cell surface. The A chain possesses RNA Nglycosidase activity that irreversibly inactivates the 28S rRNA of the mammalian 60S ribosome subunit, subsequently arresting cell protein synthesis (1). Due to its high availability and relative ease of production, ricin is considered a biological threat agent (2). The toxicity of ricin depends on the route of exposure, inhalatory exposure being considered the most severe (3). Pathological studies of pulmonary ricin intoxication have demonstrated that injury is confined mostly to the lungs (4) and characterized by a local cytokine storm, massive neutrophil recruitment, increased prooxidant enzyme activity, and development of proteinaceous pulmonary edema, subsequently resulting in respiratory failure and death (4, 5).Prophylactic antiricin vaccines are being developed (6), yet postexposure medical countermeasures are needed for treatment of unvaccinated victims after pulmonary exposure to lethal doses of the toxin. Previous studies have examined the possibility of protecting animals against pulmonary ricinosis by passive immunization with polyclonal antiricin antibodies; nevertheless, under this mode of protection, survival rates declined sharply in correlation with antitoxin administration timing following intoxication, so that antiricin antibodies administered 24 h after exposure gave rise to limited rates of survival (5, 7). At this late time point, the pathophysiological condition of some of the intoxicated mice may have deteriorated so that the loss of function of the lungs is irreversible. Conversely, we previously showed that higher sur...